These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 6775182)

  • 1. Binding of drugs to human serum albumin. XIV. The theoretical basis for the interaction between phenytoin and valproate.
    Kober A; Olsson Y; Sjöholm I
    Mol Pharmacol; 1980 Sep; 18(2):237-42. PubMed ID: 6775182
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of valproate on free plasma phenytoin concentrations.
    Tsanaclis LM; Allen J; Perucca E; Routledge PA; Richens A
    Br J Clin Pharmacol; 1984 Jul; 18(1):17-20. PubMed ID: 6430316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competition between valproate & phenytoin for plasma protein binding.
    Jaffery NF; Ahmad SN; Jailkhani BL
    Indian J Med Res; 1986 Apr; 83():426-8. PubMed ID: 3087873
    [No Abstract]   [Full Text] [Related]  

  • 4. Valproic acid: in vitro plasma protein binding and interaction with phenytoin.
    Cramer JA; Mattson RH
    Ther Drug Monit; 1979; 1(1):105-16. PubMed ID: 121944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of fosphenytoin, phosphate ester pro drug of phenytoin, to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phenylbutazone, phenytoin, valproic acid or warfarin.
    Lai CM; Moore P; Quon CY
    Res Commun Mol Pathol Pharmacol; 1995 Apr; 88(1):51-62. PubMed ID: 7620838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproic acid in epilepsy: clinical and pharmacological effects.
    Mattson RH; Cramer JA; Williamson PD; Novelly RA
    Ann Neurol; 1978 Jan; 3(1):20-5. PubMed ID: 350128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased plasma protein binding of phenytoin in patients on valproic acid.
    Dahlqvist R; Borgå O; Rane A; Walsh Z; Sjöqvist F
    Br J Clin Pharmacol; 1979 Dec; 8(6):547-52. PubMed ID: 391256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictability of unbound antiepileptic drug concentrations in children treated with valproic acid and phenytoin.
    Miles MV; Snead OC; Thorn MD
    Clin Pharm; 1988 Sep; 7(9):688-93. PubMed ID: 3149223
    [No Abstract]   [Full Text] [Related]  

  • 9. Protein binding of digitoxin, valproate and phenytoin in sera from diabetics.
    Doucet J; Fresel J; Hue G; Moore N
    Eur J Clin Pharmacol; 1993; 45(6):577-9. PubMed ID: 8157046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The quantitative effect of serum albumin, serum urea, and valproic acid on unbound phenytoin concentrations in children.
    ter Heine R; van Maarseveen EM; van der Westerlaken MM; Braun KP; Koudijs SM; Berg MJ; Malingré MM
    J Child Neurol; 2014 Jun; 29(6):803-10. PubMed ID: 23670246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valproate and palmitate binding to human serum albumin: an hypothesis on obesity.
    Brodersen R; Jørgensen N; Vorum H; Krukow N
    Mol Pharmacol; 1990 May; 37(5):704-9. PubMed ID: 2111005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproic acid and phenytoin effects on serum proteins and immunoglobulins of epileptic patients.
    Garzón P; González-Cornejo S; Román-Maldonado S; Navarro-Ruiz A
    Gen Pharmacol; 1985; 16(4):411-3. PubMed ID: 2412936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of single doses of sodium valproate on serum phenytoin levels and protein binding in epileptic patients.
    Monks A; Richens A
    Clin Pharmacol Ther; 1980 Jan; 27(1):89-95. PubMed ID: 6985856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum protein binding of diphenylhydantoin in man. II. Interaction with sodium valproate in epileptic patients.
    Gatti G; Lecchini S; Frigo GM; Visintini D; Calzetti S; Lombardi M; Cattaino G
    Farmaco Prat; 1979 Jan; 34(1):46-8. PubMed ID: 378689
    [No Abstract]   [Full Text] [Related]  

  • 15. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.
    Joerger M; Huitema AD; Boogerd W; van der Sande JJ; Schellens JH; Beijnen JH
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):133-40. PubMed ID: 16918714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Binding of phenytoin to serum albumin in vitro and in vivo].
    Pospísil J; Perlík F; Kordac V; Kolínová M
    Cesk Farm; 1991 Dec; 40(6-7):200-2. PubMed ID: 1823294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between phenytoin and valproate.
    Sansom LN; Beran RC; Schapel GJ
    Med J Aust; 1980 Aug; 2(4):212. PubMed ID: 6776391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum protein binding of valproic acid in healthy subjects and in patients with liver disease.
    Urien S; Albengres E; Tillement JP
    Int J Clin Pharmacol Ther Toxicol; 1981 Jul; 19(7):319-25. PubMed ID: 6790449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of spin labeling to drug assays. II. Determination of the binding of [14C]-phenytoin and spin-labeled phenytoins to albumin and human serum.
    Chou D; Polnaszek CF; Yost Y; Leppik IE; Holtzman JL
    Mol Pharmacol; 1981 Nov; 20(3):674-80. PubMed ID: 7329409
    [No Abstract]   [Full Text] [Related]  

  • 20. Interaction between phenytoin, 5-(p-hydroxyphenyl)-5-phenylhydantoin and valproate in the rat.
    O'Leary TD; Sansom LN
    J Pharmacol Exp Ther; 1981 Mar; 216(3):613-6. PubMed ID: 6782238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.